drugset
drugset / Trial / NCT05238064

Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

NCT05238064 ↗

Phase 1/2 Unknown 30 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The study is to investigate the safety, tolerability and efficacy of PI3Kδ inhibitor Parsaclisib in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in frontline treatment of patients with peripheral T-cell lymphoma (PTCL).

Timeline

Start
2022-03
Primary completion
2025-03
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule 2.5 mg Oral
Subject Parsaclisib Small molecule 10 mg Oral
Subject Parsaclisib Small molecule 15 mg Oral
Subject Parsaclisib Small molecule 20 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

No indication recorded.